In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Lilly’s senior VP of information and R&D IT Ramesh Durvasula said Lilly will use AI and tech to transform the company.
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly ( LLY -1.74%) is taking a shot at developing one. With the appointment of a new ...
On Friday, Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $932.06 which represents a slight increase of $21.37 or 2.35% from the prior close of $910.69. The stock opened at ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and ...
US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback